Additional beneficial effects on 'cardiometabolic risk factors' beyond those expected from weight loss in trials of the anti-obesity drug rimonabant may not be due to the drug itself, reports an article in the June issue of Drug and Therapeutics Bulletin (DTB). Advertisements for rimonabant (sold under the brand name Acomplia by Sanofi-Aventis) claim that 'an estimated 50% of the effects â?¦ on cardiometabolic risk factors are beyond those expected from weight loss alone'. [click link for full article]


Click Here to read the entire article...